Obermatt
See Similar Stocks →

Roivant Sciences

NSQ:ROIV · BMG762791017
BiotechnologyMedium

360

47
Medium confidence — indicative
Profit price97
Owner Earnings Yield1
Dividend Yield1
Price/Sales3
Price/Book16
Return on Capital40
Cash Return on Capital51
Return on Equity53
Profit margins19
Accruals17
Owner Earnings Margin6
Sales growth96
Profit growth4
Reinvestment79
Price momentum93
Debt load76
Refinancing73
Debt Payback1
Liquidity23
Analyst ratings66
Opinion Changes50
Price Target Upside46
Market mood81
Value Creation4/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Roivant Sciences doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUK
IndustryBiotechnology
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Websiteroivant.com
ISINBMG762791017
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)S&P MIDCAP (USA)D.J. US Health Care
Themes
GeneticsDermatologyRespiratoryImmunologyInflammationOphthalmologyRheumatologyPulmonologyCardiovascular

Description

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. The company’s pipeline includes brepocitinib, a potent small molecule inhibitor of JAK1 an…

Analysis

Weak and unloved

Roivant Sciences Ltd. is weak and unloved: below-average business metrics and a price that reflects that disappointment.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 4/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
93
2023202420252026

All-time high

93

Jun 2026

All-time low

25

Jan 2025

Average rank

48

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
3
1
1
1
Price/Earnings
87
100
2
2
Price/Book
16
64
6
61
Dividend Yield
1
1
1
1
Value (overall)
15
45
7
24

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Roivant Sciences with its peers
Immunovant
NSQ:IMVT
86
CountryUK
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
MindMaze Therapeutics Holding
SWX:MMTX
49
CountrySwitzerland
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
BeOne Medicines
SHH:688235
91
CountrySwitzerland
IndustryBiotechnology
SizeX-Large
Full Stock Analysis →
Anbio Biotechnology
NMQ:NNNN
—
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Innate Pharma
PAR:IPH
54
CountryFrance
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
argenx
BRU:ARGX
98
CountryNetherlands
IndustryBiotechnology
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →